Table 1.
Characteristics of patients of cohorts 1 and 2
| Characteristics | Statistics | |
|---|---|---|
| Cohort 1 | Cohort 2 | |
| Patients | 982 | 272 |
| Gender (M/F) | 392/590 (39.9/60.1) | 147/125 (54/46) |
| Age (years) | 63.9 ± 9.8 | 58.7 ± 7.4 |
| Race | Caucasian | Caucasian |
| Disease | ||
| Colorectal cancer | 740 (75.4) | 130 (47.8) |
| Gastric cancer | 193 (19.6) | 12 (4.4) |
| Breast cancer | 49 (5.0) | 130 (47.8) |
| Treatmenta | ||
| FU-LV (De Gramont regimen) | 170 (17.3) | 0 (0) |
| Capecitabine | 210 (21.4) | 92 (33.8) |
| FOLFIRI | 182 (18.5) | 0 (0) |
| FOLFOX-4 | 190 (19.3) | 130 (47.8) |
| FOLFOXIRI | 54 (5.5) | 0 (0) |
| CAPOX | 160 (16.3) | 0 (0) |
| TPF | 0 (0) | 0 (0) |
| XELIRI | 8 (0.7) | 0 (0) |
| EOXb | 8 (0.8) | 50 (18.4) |
| ADRs | ||
| Gastrointestinal | Grade≥2 | |
| Nausea/Vomiting | 16% | 0 (0) |
| Diarrhea | 39.7% | 0 (0) |
| Stomatitis | 14% | 0 (0) |
| Dermatological | Grade≥2 | |
| Hand-foot syndrome | 9.3% | 0 (0) |
| Hematological | Grade≥3 | |
| Fever | 2.2% | 0 (0) |
| Leucopenia | 12.3% | 0 (0) |
| Neutropenia | 17.4% | 0 (0) |
| Febrile neutropenia | 4.7% | 0 (0) |
| Anemia | 4.2% | 0 (0) |
| Thrombocytopenia | 5.8% | 0 (0) |
aAbbreviations listed as per NCI Thesaurus v. 16.08e (release 2016-08-29)
bEpirubicin, oxaliplatin, capecitabine